Recognizing and Improving Health Care Disparities in the Prevention of Cardiovascular Disease in Women
- 334 Downloads
Innate differences in gender physiology result in unique exposures, risk, and protection that are specific to women. Recognition and appreciation of these differences results in better treatment adaptations for women and better outcomes. Disparities between genders in the treatment of major cardiovascular risk factors still exist and are mostly secondary to underestimating or misunderstanding a woman’s risk. Preventive therapies are less often recommended to women. Women are more likely to be diagnosed and treated for hypertension, but are less likely to reach treatment goals. High-risk women—including diabetic women—are less likely to be on lipid-lowering agents and reach a low-density lipoprotein level less than 100 mg/dL. Diabetic women are less likely to achieve a hemoglobin A1c level less than 7%. Through understanding these disparities, health care providers will be better able to screen female patients and institute evidence-based therapies for the prevention of cardiovascular disease.
KeywordsGender disparities Women Cardiovascular risk factors Prevention
Clinical Trial Acronyms
Atherosclerosis Risk in Communities
Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
National Health and Nutrition Examination Survey
Study of Women’s Health Across the Nation.
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 14.• Matthews KA, Crawford SL, Chae CU, et al.: Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009, 54:2366–2373. This is a novel publication from the SWAN study looking specifically at cardiometabolic changes across the menopausal transition. CrossRefPubMedGoogle Scholar
- 16.Brunner D, Weisbort J, Meshulam N, et al.: Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol 1987, 59:1271–1276.CrossRefPubMedGoogle Scholar
- 20.Sharrett AD, Ballantyne CM, Coady SA, et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins a-I and B, and HDL density subfractions: the Atherosclerosis in Communities (ARIC) Study. Circulation 2001, 104:1108–1113.CrossRefPubMedGoogle Scholar
- 26.• Cooney MT, Dudina A, Bacquer DD, et al.: HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009, 206:611–616. This is a recent publication looking at the role HDL plays in risk for CVD using pooled data from seven European prospective trials illustrating a stronger relationship between HDL and risk prediction in women compared with men. CrossRefPubMedGoogle Scholar
- 30.Bogers RP, Bemelmans WJ, Hoogenveen RT, et al.: Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300,000 persons. Arch Intern Med 2007, 167:1720–1728.CrossRefPubMedGoogle Scholar
- 40.Pasupathi P, Bakthavathsalam G, Rao YY, et al.: Cigarette smoking-effect of metabolic health risk: a review. diabetes & metabolic syndrome: Clin Res Rev 2009, 3:120–127.Google Scholar
- 44.Agency for Healthcare Research and Quality: Cardiovascular disease and other chronic conditions in women: recent findings. Program Brief. Available at http://www.ahrq.gov/research/womheart.htm. Accessed March 30, 2010.
- 48.• Mora S, Glynn RJ, Hsia J, et al.: Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010, 121:1069–1077. This is a cutting-edge paper combining the results of the JUPITER trial’s female participants with a meta-analysis of the role statins play in CVD prevention for women. CrossRefPubMedGoogle Scholar